Objective: To investigate the function of a novel primate-specific long non-coding RNA (lncRNA), named FLANC, based on its genomic location (co-localised with a pyknon motif), and to characterise its potential as a biomarker and therapeutic target.
Design: FLANC expression was analysed in 349 tumours from four cohorts and correlated to clinical data. In a series of multiple in vitro and in vivo models and molecular analyses, we characterised the fundamental biological roles of this lncRNA. We further explored the therapeutic potential of targeting FLANC in a mouse model of colorectal cancer (CRC) metastases.
Results: FLANC, a primate-specific lncRNA feebly expressed in normal colon cells, was significantly upregulated in cancer cells compared with normal colon samples in two independent cohorts. High levels of FLANC were associated with poor survival in two additional independent CRC patient cohorts. Both in vitro and in vivo experiments demonstrated that the modulation of FLANC expression influenced cellular growth, apoptosis, migration, angiogenesis and metastases formation ability of CRC cells. In vivo pharmacological targeting of FLANC by administration of 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine nanoparticles loaded with a specific small interfering RNA, induced significant decrease in metastases, without evident tissue toxicity or pro-inflammatory effects. Mechanistically, FLANC upregulated and prolonged the half-life of phosphorylated STAT3, inducing the overexpression of VEGFA, a key regulator of angiogenesis.
Conclusions: Based on our findings, we discovered, FLANC as a novel primate-specific lncRNA that is highly upregulated in CRC cells and regulates metastases formation. Targeting primate-specific transcripts such as FLANC may represent a novel and low toxic therapeutic strategy for the treatment of patients.
Keywords: angiogenesis; colorectal cancer; gene therapy; molecular genetics; oncogenes.
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
N-BLR, a Primate-Specific Non-Coding Transcript Leads to Colorectal Cancer Invasion and MigrationI Rigoutsos et al. Genome Biol 18 (1), 98. PMID 28535802.The primate-specific N-BLR is a novel molecular contributor to the complex mechanisms that underlie metastasis in colorectal cancer and a potential novel biomarker for th …
The High Expression of Long Non-Coding RNA PANDAR Indicates a Poor Prognosis for Colorectal Cancer and Promotes Metastasis by EMT PathwayM Lu et al. J Cancer Res Clin Oncol 143 (1), 71-81. PMID 27629879.Our data suggested that lncRNA PANDAR was a novel molecule involved in CRC progression, which provided a potential prognostic biomarker and therapeutic target for new the …
A Novel Long Non-Coding RNA-KAT7 Is Low Expressed in Colorectal Cancer and Acts as a Tumor SuppressorQ Wang et al. Cancer Cell Int 19, 40. PMID 30858757.Up to now, as a novel lncRNA, lncRNA-KAT7 has not any relevant research and reports. The results confirm that the expression of lncRNA-KAT7 can inhibit the malignant phen …
Functional Role of Long Non-Coding RNA CASC19/miR-140-5p/CEMIP Axis in Colorectal Cancer Progression in vitroXD Wang et al. World J Gastroenterol 25 (14), 1697-1714. PMID 31011255.CASC19 positively regulates CEMIP expression through targeting miR-140-5p. CASC19 may possess an oncogenic function in CRC progression, highlighting its potential as an e …
Targeting Long Non-Coding RNAs in Cancers: Progress and ProspectsCH Li et al. Int J Biochem Cell Biol 45 (8), 1895-910. PMID 23748105. - ReviewPervasive transcription occurs in the human genome to generate thousands of RNA transcripts, and accumulating evidence suggested that the RNA molecules, without protein c …